The estimated effects of fibrate therapy on plasma concentration and activity of PAI-1 were independent of treatment duration and changes in plasma triglyceride levels in the meta-regression analysis .
This meta- analysis of RCTs suggested that fibrate therapy does not reduce plasma concentration or activity of PAI-I. The putative benefits of fibrate therapy in patients with cardiovascular disease appear to be exerted via mechanisms independent of effects on PAI-1
OBJECTIVE The aim of this systematic review was to perform a meta- analysis of r and omized controlled trials ( RCTs ) examining the efficacy of fibrate therapy in reducing plasma concentration or activity of plasminogen activator inhibitor 1 ( PAI-1 ) .
Effect of micronized fenofibrate on plasma lipoprotein levels and hemostatic parameters of hypertriglyceridemic patients with low levels of high-density lipoprotein cholesterol in the fed and fasted state.
A r and omized , double-blind , placebo-controlled study was undertaken in 20 hypertriglyceridemic men [ plasma triglyceride ( TG ) , > 2.3 mM ] with low levels ( < 0.9 mM ) of high-density lipoprotein cholesterol ( HDL-C ) to investigate the ability of micronized fenofibrate ( Tricor or Lipidil ; 200 mg/day ) to affect atherogenic and thrombogenic plasma risk factors in the fed and fasted state . Each patient underwent ( a ) 4 weeks of dietary stabilization , ( b ) 8 weeks of treatment with fenofibrate or placebo , ( c ) a 5-week washout period , and ( d ) 8-weeks of treatment with the alternative medication . An oral fat-loading test ( 1 g fat/kg body weight ) was carried out after both treatment periods . Before treatment , patients had a mean ( + /- SD )  total plasma TG of 3.31+/-0.93 mM ; total  C , 5.75+/-0.89 mM ; HDL-C , 0.71+/-0.09 mM ; and low-density lipoprotein (LDL)-C , 3.40+/-0.68 mM. Compared with placebo , fenofibrate reduced fasting TG levels by 36 % , and triglyceride-rich lipoprotein ( TRL , d<1.006 g/ml ) -TG , and TRL-C levels by approximately 40 % . In the postpr and ial state , fenofibrate reduced total TG , TRL-TG , TRL-C , TRL-apoC-III , and TRL-apoE levels by -35 % ( all values of p<0.01 ) . Fasted and fed HDL-C and apoA-I levels were increased -10 % , and total cholesterol/HDL cholesterol ratios were decreased -15 % by fenofibrate . No significant differences were observed in mean LDL-C and LDL-apoB levels . A 6 % increase in the LDL-C/LDL-apoB ratio during fenofibrate treatment indicated a shift to larger , more buoyant LDL particles . A small , but statistically significant ( p<0.01 ) increase was observed in fasted and fed Lp(a ) levels during fenofibrate treatment . Hemostatic parameters were not significantly affected by fenofibrate , except for a 12 - 15 % decrease ( p<0.05 ) in fibrinogen levels in the fasted and fed state , and a significant increase ( 43 % ; p<0.05 ) in fasting levels of plasminogen activator-inhibitor-1 . These data demonstrate that micronized fenofibrate is highly effective , in both the fed and fasted state , in reducing TRL lipids and apolipoproteins , and in reducing plasma fibrinogen levels of men with an atherogenic lipoprotein profile
The estimated effects of fibrate therapy on plasma concentration and activity of PAI-1 were independent of treatment duration and changes in plasma triglyceride levels in the meta-regression analysis .
This meta- analysis of RCTs suggested that fibrate therapy does not reduce plasma concentration or activity of PAI-I. The putative benefits of fibrate therapy in patients with cardiovascular disease appear to be exerted via mechanisms independent of effects on PAI-1
OBJECTIVE The aim of this systematic review was to perform a meta- analysis of r and omized controlled trials ( RCTs ) examining the efficacy of fibrate therapy in reducing plasma concentration or activity of plasminogen activator inhibitor 1 ( PAI-1 ) .